Search results for "double-blind method"

showing 10 items of 631 documents

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

2022

AbstractThe STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The co-primary endpoints were the percentage change in body weight and achievement of weight loss of ≥5% at week 104. Efficacy was assessed among all randomized participants regardless of treatment discontinuation or rescue intervention. From 5 October 2018 to 1 February 2019, 304 participants were randomly assigned to semaglutide 2.4 mg (n = 152) or placebo (n = 152), 92.8% of whom completed the trial (attended t…

AdultMaleGlucagon-Like PeptideHypoglycemic AgentObesidadInvestigación médicaGeneral MedicineMiddle AgedOverweightWeight LoGeneral Biochemistry Genetics and Molecular BiologyTratamiento médicoTreatment OutcomeDouble-Blind MethodDiabetes Mellitus Type 2GlucemiaControl glucémicoFemaleObesitySettore MED/49 - Scienze Tecniche Dietetiche ApplicateHuman
researchProduct

A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease

2007

BACKGROUND: Treatment of celiac disease (CD) is based on the avoidance of gluten-containing food. However, it is not known whether trace amounts of gluten are harmful to treated patients. OBJECTIVE: The objective was to establish the safety threshold of prolonged exposure to trace amounts of gluten (ie, contaminating gluten). DESIGN: This was a multicenter, double-blind, placebo-controlled, randomized trial in 49 adults with biopsy-proven CD who were being treated with a gluten-free diet (GFD) for > or =2 y. The background daily gluten intake was maintained at < 5 mg. After a baseline evaluation (t0), patients were assigned to ingest daily for 90 d a capsule containing 0, 10, or 50 mg glute…

AdultMaleGluten free diet Celiac Diseasemedicine.medical_specialtyGlutensPlacebo-controlled studyMedicine (miscellaneous)gastroenterologyDiseasedigestive systemGastroenterologyCoeliac diseaselaw.inventionRandomized controlled trialDouble-Blind Methodgluten-free dietlawInternal medicineImmunopathologyIntestine SmallMedicineHumansgluten toxicitysmall-intestinal morphometryLymphocyte CountProspective StudiesIntestinal MucosaProspective cohort studyAutoantibodiesceliac disease; gastroenterology; gluten threshold in gluten-free food; gluten threshold in gluten-free food.; gluten toxicity; gluten-free diet; small-intestinal morphometrychemistry.chemical_classificationNutrition and DieteticsDose-Response Relationship Drugbusiness.industrynutritional and metabolic diseasesMiddle Agedmedicine.diseaseGlutendigestive system diseasesgluten threshold in gluten-free foodchemistryToxicityFemalebusinessceliac disease
researchProduct

Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern…

2005

We tested the hypothesis that gemfibrozil has a differential effect on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclass distributions and postprandial lipemia that is different in subjects classified as having LDL subclass pattern A or LDL pattern B who do not have a classic lipid disorder. Forty-three normolipemic subjects were randomized to gemfibrozil (1,200 mg/day) or placebo for 12 weeks. Lipids and lipoproteins were determined by enzymatic methods. The mass concentrations of lipoproteins in plasma were determined by analytic ultracentrifugation and included the S(f) intervals: 20 to 400 (very LDL), 12 to 20 (intermediate-density lipoprotein), 0 to 12 (LDL), an…

AdultMaleHyperlipoproteinemiasmedicine.medical_specialtySmall dense ldlLipid disorderApolipoprotein BLipoproteins VLDLPlacebochemistry.chemical_compoundDouble-Blind MethodInternal medicinemedicineHumansGemfibrozilTriglyceridesAgedHypolipidemic Agentsbiologybusiness.industryMiddle AgedPostprandial PeriodLipoproteins LDLTreatment OutcomeEndocrinologyPostprandialchemistryLow-density lipoproteinbiology.proteinFemalelipids (amino acids peptides and proteins)GemfibrozilLipoproteins HDLCardiology and Cardiovascular MedicinebusinessGemfibrozil small low-density lipoprotein pattern B pattern ABiomarkersLipoproteinmedicine.drug
researchProduct

A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia.

1996

A double-blind, randomized, parallel study in 167 hospitalized patients with major depression and melancholia was conducted to determine if rapidly escalated doses of venlafaxine produced an earlier response, compared with rapidly escalated doses of imipramine. The daily dose of venlafaxine was rapidly increased to 375 mg/day over a five-day period, was maintained at this level for 10 days, and then was reduced to 150 mg/day for the remainder of the study. The imipramine dose was rapidly increased to 200 mg/day over five days and was maintained at this level to the end of the study. The primary efficacy variables were time to response and time to sustained response on the HAM-D and MADRS. N…

AdultMaleImipraminePersonality Inventorymedicine.medical_treatmentVenlafaxineAntidepressive Agents TricyclicImipramineDrug Administration ScheduleDouble blindDouble-Blind MethodMelancholiamedicineHumansBiological PsychiatryDepression (differential diagnoses)Rapid responseChemotherapyDepressive DisorderDose-Response Relationship DrugVenlafaxine HydrochlorideParallel studyMiddle AgedCyclohexanolsPsychiatry and Mental healthTreatment OutcomeAnesthesiaAntidepressive Agents Second-GenerationFemalemedicine.symptomPsychologymedicine.drugJournal of psychiatric research
researchProduct

Subchronic Antidepressant Treatment with Venlafaxine or Imipramine and Effects on Blood Pressure and Heart Rate: Assessment by Automatic 24-Hour Moni…

1996

Venlafaxine is a new nontricyclic antidepressant inhibiting the reuptake of serotonin, noradrenaline, and, to a lesser extent, dopamine without antagonizing cholinergic, histaminergic, or noradrenergic receptors. Significantly, in a first placebo-controlled safety and efficacy study, high doses of venlafaxine increased blood pressure in some study subjects. In order to investigate further the effect of subchronic antidepressant drug treatment on blood pressure and heart rate, the effects of a conventional tricyclic (imipramine) and a structurally different phenethylamine antidepressant (venlafaxine) were compared. Sixteen inpatients with major depression (melancholic type) were treated for …

AdultMaleImipramineVenlafaxine HydrochlorideHemodynamicsBlood PressureVenlafaxineAntidepressive Agents TricyclicImipramineDouble-Blind MethodHeart RateHeart ratemedicineHumansPharmacology (medical)Psychiatric Status Rating ScalesDepressive Disorderbusiness.industryVenlafaxine HydrochlorideGeneral MedicineBlood Pressure Monitoring AmbulatoryMiddle AgedCyclohexanolsPsychiatry and Mental healthBlood pressureAnesthesiaCirculatory systemAntidepressive Agents Second-GenerationAntidepressantFemalebusinessmedicine.drugPharmacopsychiatry
researchProduct

Drug treatment of panic disorder: early response to treatment as a predictor of final outcome

1990

One of the core problems in clinical research is the detection of early changes in target symptoms that predict future therapeutic outcome. To analyze potential predictors of outcome, data of a multicenter study on patients with panic disorder were used. A total of 1010 patients were randomly allocated either to alprazolam, imipramine or placebo treatment. Early improvement in the number of spontaneous panic attacks within the first week of treatment predicted outcome exclusively in the alprazolam group. In contrast, placebo responders and nonresponders were differentiated by early changes in anticipatory anxiety intensity. For tricyclic antidepressants such as imipramine an evaluation peri…

AdultMaleImipraminemedicine.medical_specialtyPlaceboImipramineDouble-Blind MethodInternal medicinemedicineHumansPsychiatryAgoraphobiaPsychiatric Status Rating Scaleschemistry.chemical_classificationAlprazolamPanic disorderPanicmedicine.diseaseAnxiety DisordersPanicPsychiatry and Mental healthClinical researchchemistryAlprazolamAnxietyFemalemedicine.symptomArousalPsychologyTricyclicmedicine.drugActa Psychiatrica Scandinavica
researchProduct

Subtyping panic disorder by major depression and avoidance behaviour and the response to active treatment

1991

In order to establish the clinical validity of currently used ways of subtyping panic disorder the predictive power of associated current avoidance behaviour and (secondary) major depression for the response to active treatment (alprazolam, imipramine) was tested. The analysis was based on the data from the Cross-National-Collaborative-Panic-Study. Limited support for validity evidenced by predicting drug response was found for grading panic disorder by the severity of avoidance behaviour; patients with panic attacks and agoraphobia are more responsive to imipramine (compared with alprazolam) when using the reduction of the total number of panic attacks (or of spontaneous panic attacks) as …

AdultMaleImipraminemedicine.medical_specialtySocial Environmentbehavioral disciplines and activitiesImipraminelaw.inventionDouble-Blind MethodRandomized controlled triallawmental disordersmedicineHumansPharmacology (medical)PsychiatryAgoraphobiaBiological PsychiatryDepression (differential diagnoses)Psychiatric Status Rating ScalesDepressive DisorderAlprazolamPanic disorderPanicGeneral MedicinePrognosismedicine.diseaseAnxiety DisordersPanichumanitiesSubtypingPsychiatry and Mental healthAlprazolamFemalemedicine.symptomPsychologymedicine.drugAgoraphobiaClinical psychologyEuropean Archives of Psychiatry and Clinical Neuroscience
researchProduct

The efficacy of acupuncture in human pain models: A randomized, controlled, double-blinded study

2012

Acupuncture is frequently used to treat pain, although data supporting the analgesic efficacy from placebo-controlled studies is sparse. In order to get evidence for acupuncture analgesia we performed a study with 2 well-recognized experimental human pain models - the cold-pressor (CP) test and intradermal capsaicin injection. Fifty healthy men were included. Our study compared Traditional Chinese Medicine-based acupuncture to sham acupuncture with Streitberger placebo needles in a randomized, controlled, double-blinded trial. The primary endpoint was the reduction of mean pain intensity during 3minutes of CP test or of mean pain intensity within 10minutes after capsaicin injection. Seconda…

AdultMaleInjections IntradermalAnalgesicTraditional Chinese medicinePlacebolaw.inventionDouble-Blind MethodRandomized controlled triallawmedicineAcupunctureHumansPain ManagementAcupuncture AnalgesiaMedicine Chinese TraditionalPain Measurementbusiness.industryCold pressor testCold TemperatureTreatment OutcomeAnesthesiology and Pain MedicineAllodyniaNeurologyAnesthesiaSensory System AgentsHyperalgesiaNeurology (clinical)Capsaicinmedicine.symptombusinessPain
researchProduct

Ocular Changes in Patients With Mucopolysaccharidosis I Receiving Enzyme Replacement Therapy

2007

Objective To describe the progression of ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy. Methods Three male and five female patients with mucopolysaccharidosis I were followed up for 4 years while undergoing enzyme replacement therapy with α-L-iduronidase (Aldurazyme). Visual acuity, corneal clouding, intraocular pressure, ophthalmoscopy, and optic disc measurements were performed yearly. Results Vision remained stable in 5 patients and deteriorated by at least 2 Snellen lines in 3 patients. Deterioration in 2 of these patients was related to progressive corneal clouding. Visual acuities improved in 1 patient after bilateral penetrating keratopl…

AdultMaleIntraocular pressuremedicine.medical_specialtyVisual acuityAdolescentgenetic structuresMucopolysaccharidosis Imedicine.medical_treatmentOptic DiskVisual AcuityCorneal DiseasesIduronidaseDouble-Blind MethodOptic Nerve DiseasesMucopolysaccharidosis IHumansMedicineChildInfusions IntravenousPapilledemaIntraocular PressureCorneal transplantationbusiness.industryEnzyme replacement therapyRecombinant Proteinseye diseasesSurgeryOphthalmoscopyOphthalmologymedicine.anatomical_structureDisease ProgressionOptic nerveFemalesense organsmedicine.symptombusinessOptic discArchives of Ophthalmology
researchProduct

Effects of myofascial release in erector spinae myoelectric activity and lumbar spine kinematics in non-specific chronic low back pain: Randomized co…

2019

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.sciencedirect.com/science/article/abs/pii/S0268003318300330?via%3Dihub This is the pre-peer reviewed version of the following article: Arguisuelas, M.D., Lisón, J.F., Doménech-Fernández, J., Martínez-Hurtado, I., Salvador Coloma, P. & Sánchez-Zuriaga, D. (2019). Effects of myofascial release in erector spinae myoelectric activity and lumbar spine kinematics in non-specific chronic low back pain: randomized controlled trial. Clinical Biomechanics, vol. 63, pp. 27-33, which has been published in final form at https://doi.org/10.1016/j.clinbiomech.2019.02.009 Este es el pre-print del siguiente…

AdultMaleManipulation Spinalmedicine.medical_specialtySíndrome de dolor miofascial - Fisioterapia.Myofascial releaseParaspinal MusclesBiophysicsMyofascial pain syndromes - Physical therapy.ElectromyographySpinal manipulationlaw.invention03 medical and health sciences0302 clinical medicineLumbarDouble-Blind MethodRandomized controlled triallawmedicineHumansOrthopedics and Sports MedicineLow back painRange of Motion ArticularFasciaBackache - Treatment.MassageLumbar VertebraeRelaxation (psychology)medicine.diagnostic_testbusiness.industryElectromyographyPhysical therapy modalitiesDolor de espalda - Electromiografía.Lumbosacral Region030229 sport sciencesFasciaMiddle AgedBackache - Electromyography.Low back painBiomechanical PhenomenaMyofascial releasemedicine.anatomical_structurePhysical therapyFemalemedicine.symptomDolor de espalda - Tratamiento.businessLow Back Pain030217 neurology & neurosurgery
researchProduct